ARV-393 is an orally bioavailable PROTAC designed to promote the degradation of BCL6 through the ubiquitin-proteasome pathway. Its structure incorporates ligand conjugates that specifically target BCL6 and the E3 ligase cereblon. This compound shows significant activity in various cell lines associated with diffuse large B-cell lymphoma and Burkitt lymphoma, demonstrating effective tumor suppression in xenograft models.
Usually ships within 24 hours.